112362-50-2
中文名称
达福普汀
英文名称
Dalfopristin
CAS
112362-50-2
分子式
C34H50N4O9S
分子量
690.854
MOL 文件
112362-50-2.mol
更新日期
2023/03/20 15:41:19
112362-50-2 结构式
基本信息
中文别名
达福司汀达福普汀
达福司汀杂质
达福普丁甲磺酸
(1(2)Z,3(2)S,3(3)R,6R,7R,17S)-3(3)-((2-(二乙氨基)乙基)磺酰基)-17-羟基-6-异丙基-7,15-二甲基-5-氧杂-11-氮杂-1(4,2)-噁唑-3(1,2)-吡咯烷酰基二十碳六烯酸-8,13,15-三烯-2,4,10,19-四酮
(3R,4R,5E,10E,12E,14S,26R,26AS)-26-[[2-(二乙氨基)乙基]磺酰基]-8,9,14,15,24,25,26,26A-八氢-14-羟基-4,12-二甲基-3-(1-甲基乙基)-3H-21,18-腈-1H,22H-吡咯并[2,1-C][1,8,4,19] DIOXADIAZAZACYCLOTETRACOSINE-1,7,16,22(4H,17H)-四酮
英文别名
RP 54476112362-50-2
Dalfopristin
Dalfopristin Mesylate
(3R,4R,5E,10E,12E,14S,26R,26aS)-26-[[2-(Diethylamino)ethyl]sulfonyl]-8,9,14,15,24,25,26,26a-octahydro-14-hydroxy-4,12-dimethyl-3-(1-methylethyl)-3H-21,18-nitrilo-1H,22H-pyrrolo[2,1-c][1,8,4,19]dioxadi
(3R,4R,5E,10E,12E,14S,26R,26aS)-26-[[2-(DiethylaMino)ethyl]sulfonyl]-8,9,14,15,24,25,26,26a-octahydro-14-hydroxy-4,12-diMethyl-3-(1-Methylethyl)-3H-21,18-nitrilo-1H,22H-pyrrolo[2,1-c][1,8,4,19]dioxadiazacyclotetracosine-1,7,16,22(4H,17H)-tetr
(3R,4R,5E,10E,12E,14S,26R,26aS)-26-[[2-(Diethylamino)ethyl]sulfonyl]-8,9,14,15,24,25,26,26a-octahydro-14-hydroxy-4,12-dimethyl-3-(1-methylethyl)-3H-21,18-nitrilo-1H,22H-pyrrolo[2,1-c][1,8,4,19]dioxadiazacyclotetracosine-1,7,16,22(4H,17H)-tetrone
3H-21,18-Nitrilo-1H,22H-pyrrolo[2,1-c][1,8,4,19]dioxadiazacyclotetracosine-1,7,16,22(4H,17H)-tetrone, 26-[[2-(diethylamino)ethyl]sulfonyl]-8,9,14,15,24,25,26,26a-octahydro-14-hydroxy-4,12-dimethyl-3-(1-methylethyl)-, (3R,4R,5E,10E,12E,14S,26R,26aS)-
所属类别
原料药：抗生素类药物物理化学性质
熔点~150°
沸点940.5±65.0 °C(Predicted)
密度1.27±0.1 g/cm3(Predicted)
储存条件-20°C储存
溶解度DMSO:113.0(Max Conc. mg/mL);163.57(Max Conc. mM)
Ethanol:100.0(Max Conc. mg/mL);144.75(Max Conc. mM)
Ethanol:100.0(Max Conc. mg/mL);144.75(Max Conc. mM)
酸度系数(pKa)13.18±0.70(Predicted)
常见问题列表
应用
达福普汀(Dalfopristin)为链阳菌素普那霉素IIA的半合成衍生物，达福普汀和奎奴普丁(Quinupristin)以70/30(w/w)比例组成的抗生素协同复合制剂于1999年9月首次上市，商品名：主要用于治疗成人致命性耐万古霉素屎肠球菌(VREF)菌血症相关性感染、耐甲氧西林金黄色葡萄球菌(MRSA)及化脓性链球菌引起的皮肤及软组织感染。概述
达福普汀(Dalfopristin)为链阳菌素普那霉素IIA的半合成衍生物，达福普汀和奎奴普丁(Quinupristin)以70/30(w/w)比例组成的抗生素协同复合制剂于1999年9月首次上市，商品名：主要用于治疗成人致命性耐万古霉素屎肠球菌(VREF)菌血症相关性感染、耐甲氧西林金黄色葡萄球菌(MRSA)及化脓性链球菌引起的皮肤及软组织感染。生物活性
Dalfopristin (RP54476) 是ostreogyrcin A的半合成类似物。Quinupristin/dalfopristin (Q/D) 是一种亲本链霉菌素，其活性范围包括革兰氏阳性病原体，及对其他种类的抗菌化合物具有抗性的病原体。靶点
Antibacterial
体外研究
Quinupristin/Dalfopristin(Q/D) is a combination of streptogramins B (Quinupristin) and streptogramins A (Dalfopristin) at 30:70 ratio. Quinupristin/Dalfopristin, a semisynthetic injectable streptogramin, is a combination of 2 synergistic antibiotic components that are derived from pristinamycin: a type B streptogramin (Quinupristin) and a type A streptogramin (Dalfopristin), in a 30:70 weight-to-weight ratio.